KDM5C and glioma: In this regard, the discovery of potent histone demethylase inhibitors across the JMJ family abled to inhibit glioma cell proliferation, such as GSK-J1/J4, encourages the design of new small-molecule inhibitors with selective pharmacological intervention against KDM5C [77,78,79].